鼻内氯胺酮与静脉阿片类药物治疗急诊肾绞痛疼痛:系统评价与Meta分析
该系统评价与Meta分析共纳入4项随机对照试验、454例肾绞痛患者,其中230例(50.6%)接受鼻内氯胺酮,对照为静脉吗啡或芬太尼。主要结局为各时间点疼痛强度(VAS/NRS)。结果显示,5分钟(平均差:-0.41 VAS/NRS,95%CI:-1.88至1.07,P=0.59)、15分钟(平均差:-0.20 VAS/NRS,95%CI:-0.86至0.46,P=0.56)和30分钟(平均差:0.53 VAS/NRS,95%CI:-0.08至1.13,P=0.09)疼痛评分组间均无显著差异。补救镇痛需求及不良事件(恶心、头晕)发生率亦无显著差异。
要点
- 鼻内氯胺酮与静脉阿片类药物在急诊肾绞痛5分钟镇痛效果相当(平均差:-0.41 VAS/NRS,95%CI:-1.88至1.07,P=0.59)。
- 15分钟镇痛效果组间无显著差异(平均差:-0.20 VAS/NRS,95%CI:-0.86至0.46,P=0.56)。
- 30分钟镇痛效果组间无显著差异(平均差:0.53 VAS/NRS,95%CI:-0.08至1.13,P=0.09)。
- 补救镇痛需求、不良事件、恶心和头晕发生率在鼻内氯胺酮与静脉阿片类药物之间无显著差异。
- 鼻内途径作为微创且省时的替代方案,在急诊肾绞痛镇痛中显示出与静脉阿片类相当的疗效和安全性。
适用人群与场景
- 急诊科肾绞痛患者,纳入比较鼻内氯胺酮与静脉吗啡或静脉芬太尼的随机对照试验。
处置流程与药物剂量
- 鼻内氯胺酮作为主要干预措施,对照为静脉吗啡或芬太尼。
研究设计与关键结果
- 系统评价与Meta分析纳入4项随机对照试验,共454例患者,其中230例(50.6%)接受鼻内氯胺酮。
- 5分钟疼痛评分组间无显著差异(平均差:-0.41 VAS/NRS,95%CI:-1.88至1.07,P=0.59)。
- 15分钟疼痛评分组间无显著差异(平均差:-0.20 VAS/NRS,95%CI:-0.86至0.46,P=0.56)。
- 30分钟疼痛评分组间无显著差异(平均差:0.53 VAS/NRS,95%CI:-0.08至1.13,P=0.09)。
- 补救镇痛需求和不良事件(恶心、头晕)发生率组间无显著差异。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入4项随机对照试验。
对床旁实践的改变
- 对于急诊肾绞痛患者,鼻内氯胺酮在5、15、30分钟镇痛效果与静脉阿片类相当,且不良事件和补救镇痛需求无增加,可考虑作为静脉阿片类的替代选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND AND IMPORTANCE: Renal colic pain is typically managed using intravenous opioids, but the intranasal route has emerged as a less invasive and time-efficient alternative. Intranasal ketamine has shown promise as a safe and effective analgesic for acute pain in emergency settings.
OBJECTIVE: To compare the efficacy and safety of intranasal ketamine versus intravenous opioids for renal colic pain management in the emergency department.
DESIGN, SETTINGS, AND PARTICIPANTS: PubMed, Embase, and Cochrane were systematically searched for randomized controlled trials (RCTs) comparing intranasal ketamine to intravenous morphine or intravenous fentanyl in patients with renal colic.
INTERVENTION OR EXPOSURE: Intranasal ketamine as the primary intervention; comparators were intravenous morphine or fentanyl.
OUTCOMES, MEASURE, AND ANALYSIS: The primary outcome was pain intensity at various time points, measured using the Visual Analog Scale (VAS) and Numerical Rating Scale (NRS). Secondary outcomes: need for rescue analgesia, incidence of adverse events, nausea, and dizziness. Data were pooled using random-effects models to calculate mean differences for continuous outcomes and risk ratios for binary outcomes, with 95% confidence intervals (CIs). All statistical analyses were performed using R Software, version 4.2.3.
MAIN RESULTS: We included four RCTs, involving 454 patients, of whom 230 (50.6%) received intranasal ketamine. There were no significant differences between groups in pain scores at 5 min (mean difference: -0.41 VAS/NRS, 95% CI: -1.88 to 1.07, P = 0.59), 15 min (mean difference: -0.20 VAS/NRS, 95% CI: -0.86 to 0.46, P = 0.56), and 30 min (mean difference: 0.53 VAS/NRS, 95% CI: -0.08 to 1.13, P = 0.09). No significant differences were found between groups in the need for rescue analgesia or in the incidence of adverse events, nausea, or dizziness.
CONCLUSION: Intranasal ketamine demonstrated analgesic efficacy comparable to intravenous opioids at 5, 15, and 30 min, with no increase in adverse events or rescue analgesia requirements.
参考来源
- Scapin M, Neto ES, da Silva PHT, et al. Intranasal ketamine versus intravenous opioids for renal colic pain in the emergency department: a systematic review and meta-analysis. Eur J Emerg Med. 2025. PMID: 41439724. doi:10.1097/MEJ.0000000000001302
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。